glp-1 receptor agonists adverse effects GI of Glucagon-Like Peptide-1 GLP1 Receptor Agonists—Effects beyond Obesity

Pregnancy and breastfeeding also require stopping these medications

News provided by Ro Apr 09, 2026, 07:15 ET Foundayo gives patients a new once daily pill option and expands Ro's comprehensive weight loss formulary NEW YORK, April 9, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Company's newest oral GLP-1 innovation on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s

The longer answer depends on which clinical trial data you reference, your prior experience with GLP-1 agonists, and your individual tolerance profile

Thus, although an important point to keep attention to, data so far does not indicate that cardiovascular complications are a major cause for concern at the moment (gastrointestinal problems being by far the larger problem experienced by people on GLP1R agonists )

Glucagon-like peptide-1 receptor signaling in the lateral parabrachial nucleus contributes to the control of food intake and motivation to feed